The publication describes the discovery of a novel series of Imidazopyrazine derivatives by IRBM’s drug discovery team. This novel series of SHP2 allosteric inhibitors, having an imidazopyrazine 6,5-fused heterocyclic system as central scaffold, showed an excellent potency in enzyme and cellular assays.
IRBM participating in EATRIS Quality Initiative
At IRBM, we are aware that a screening campaign’s success is critically dependent on the quality and reproducibility of the assays used. Together with the NIH, academic institutions and pharmaceutical companies, we are participating in an EATRIS consortium initiative to help investigate this issue. This collaboration is the first systematic study by translational scientists into the reproducibility of high-throughput screening (HTS) campaigns.
Learn more here.
Related Posts
